newsfilter
← Latest News
Business Wire·

Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights

Enrollment on track in both Phase 2b chronic pain studies with NYX-2925—data readouts expected 1H 2022 Enrollment on track in Phase 2 cognitive impairment study with NYX-458—data readout expected 2H 2022 Completed FDA meeting on NYX-783 develo